Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Cardio Conversations: Abbott's Electrophysiology CMO Christopher Piorkowski On Cardiac Mapping, PFA, VT And More

Executive Summary

In this episode of Medtech Insight’s new podcast series focused on cardiovascular technology, editor Reed Miller talked to Christopher Piorkowski, Abbott's chief medical officer for electrophysiology.

After a two-decade career as a electrophysiologist specializing in complex cardiac arrhythmias, Christopher Piorkowski left his job as the head of the department of electrophysiology at the University of Dresden to join Abbott in 2020.

As the chief medical officer of Abbott's electrophysiology business, Piorkowski has "an opportunity [to] build future medical technology [and] help many patients – not only the one on the table," he told Medtech Insight. "So far the experience has been outstanding."

According to Meddevicetracker, Abbott has the second largest share of the cardiac ablation device market behind Johnson & Johnson/Biosense Webster, but ahead of Medtronic and Boston Scientific

Abbott is depending on the EnSite X arrhythmia mapping system to maintain its position in this increasingly competitive market. "We are building the most accurate, most user-friendly and most flexible tracking technology in the field of electrophysiology."  (Also see "Abbott Launches Next-Generation Of EnSite Cardiac Mapping System" - Medtech Insight, 5 Nov, 2020.)

The company is also continuing to push innovation in cardiac ablation technology, including pulsed field ablation (PFA), but all of those advanced tools will be designed around EnSite, he said. (Also see "News We’re Watching – LivaNova And Medtronic Recalls; Approvals For Abbott And Guardant; Pediatric Device Grants" - Medtech Insight, 3 Feb, 2023.)

"The EnSite X system is really the foundation of our future," he said

Medtech Insight editor Reed Miller recently interviewed Piorkowski to to learn more about the company's technological and market strategy, his priorities in the company, and more. 

Use the player below to hear the whole interview.



Further Reading

Our other podcasts are available on Apple PodcastsGoogle PodcastsSoundCloud and TuneIn - also now on Spotify Podcasts - and via smart speakers if one of these platforms has been set up as your default podcast provider.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts